Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

Conference Call Scheduled for September 17 at 10:30 ET, 7:30 PT

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for its fiscal fourth quarter and year ended June 30, 2007 and announced a planned 1-for-7 reverse split of its common stock.

For fiscal year 2007, the Company reported revenue of $17.7 million, a 44% increase over last year's revenue of $12.3 million. The net loss for fiscal 2007 was $14.1 million, or $0.47 per share, compared with a net loss of $27.8 million, or $0.98 per share, in fiscal year 2006. At June 30, 2007, the Company's balance of available cash, cash equivalents and investment securities was $8.9 million.

For the fourth quarter ended June 30, 2007, the Company reported revenue of $4.0 million compared to $4.3 million for the same period in 2006. The net loss for the quarter ended June 30, 2007 was $4.2 million, or $0.13 per share, compared with a net loss of $4.8 million, or $0.16 per share, for the same period in 2006.

For the fiscal year ended June 30, 2007, the Company reported revenue of $17.7 million consisting of $6.9 million of royalty fees earned from the commercial sales of memantine by Merz + Co. GmbH & Co. (Merz) and its marketing partners in the United States and certain European countries, $5.5 million from the sale of NTI's rights and assets related to XERECEPT(R) to Celtic Pharmaceutical Holdings L.P. (Celtic), and $5.3 million from the reimbursement of the direct expenses incurred for services provided to Celtic for administering the Phase III clinical trials for XERECEPT in the United States. The Company's fiscal year 2006 revenues of $12.3 million
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014   SunTrust Robinson Humphrey ... veterans to its equity research team in biotechnology ... expansion in equity research demonstrates our commitment to ... to enhance their investment decision making," said ... "We continue to make significant investments in differentiated ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
(Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... VENTURA, Calif., Dec. 12 VivoMetrics Inc., a ... the,appointment of Howard R. Baker to the position ... Paul Kennedy, who will remain with,the company in ... Baker joins VivoMetrics with over 28 years in ...
... Oral Iclaprim, "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic ... First Modules ... Arpida Ltd,(SWX: ARPN) announced today the enrolment and dosing of ... iclaprim in the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) ...
... for the First Time on 50 mg/Day Dose for PRISTIQ ... Treatment of ... a division of Wyeth (NYSE: WYE ), announces that ... serotonin-norepinephrine reuptake inhibitor (SNRI), showed,that adult patients who received a ...
Cached Biology Technology:VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:8/31/2014)... CAMBRIDGE, MA -- Over the past several decades, malaria diagnosis ... a patient, a technician smears the blood across a glass ... a microscope for the Plasmodium parasite, which causes the disease. ... are in the blood an important measure of disease ... for human error. , A research team from the Singapore-MIT ...
(Date:8/29/2014)... surprising discoveries about the body,s initial responses to ... team found that specialized cells in the intestine ... invasion and are the source of gut inflammation ... , Though aimed at the presence of ... that provides a barrier to protect the body ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Rome, Italy: Scientists have discovered that when they ... not only does the procedure make the mice fertile ... their lifespan. The question now is: could ovarian transplants ... Kagawa will tell the 26th annual meeting of the ...
... chemistry sets, ham radio, amateur astronomy, and early computing? ... Today, over 2,000 people from around the world belong ... from microbial fuel cells, low-cost lab equipment, environmental surveillance, ... Synthetic Biology Project at the Woodrow Wilson Center is ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has found ... their shelf life by about a week. Avtar Handa, ... increases production of a compound that slows aging and delays ... the early online version of The Plant Journal , ...
Cached Biology News:Ovarian transplantation restores fertility to old mice and also lengthens their lives 2Ovarian transplantation restores fertility to old mice and also lengthens their lives 3Gene leads to longer shelf life for tomatoes, possibly other fruits 2
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: